NASDAQ:OFIX

Orthofix Medical Stock Forecast, Price & News

$41.75
-0.40 (-0.95 %)
(As of 06/18/2021 01:23 PM ET)
Add
Compare
Today's Range
$41.75
$42.28
50-Day Range
$40.13
$45.25
52-Week Range
$28.03
$48.50
Volume513 shs
Average Volume86,919 shs
Market Capitalization$816.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.15
30 days | 90 days | 365 days | Advanced Chart
Receive OFIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Orthofix Medical and its competitors with MarketBeat's FREE daily newsletter.


Orthofix Medical logo

About Orthofix Medical

Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.04 out of 5 stars

Medical Sector

1082nd out of 2,100 stocks

Surgical & Medical Instruments Industry

102nd out of 174 stocks

Analyst Opinion: 1.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Orthofix Medical (NASDAQ:OFIX) Frequently Asked Questions

Is Orthofix Medical a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Orthofix Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OFIX, but not buy additional shares or sell existing shares.
View analyst ratings for Orthofix Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Orthofix Medical?

Wall Street analysts have given Orthofix Medical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Orthofix Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Orthofix Medical's next earnings date?

Orthofix Medical is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Orthofix Medical
.

How were Orthofix Medical's earnings last quarter?

Orthofix Medical Inc. (NASDAQ:OFIX) posted its earnings results on Friday, April, 30th. The medical device company reported $0.17 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.07 by $0.10. The medical device company had revenue of $105.59 million for the quarter, compared to analysts' expectations of $95.40 million. Orthofix Medical had a positive trailing twelve-month return on equity of 1.93% and a negative net margin of 7.11%.
View Orthofix Medical's earnings history
.

How has Orthofix Medical's stock price been impacted by Coronavirus (COVID-19)?

Orthofix Medical's stock was trading at $30.67 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OFIX shares have increased by 36.1% and is now trading at $41.75.
View which stocks have been most impacted by COVID-19
.

What guidance has Orthofix Medical issued on next quarter's earnings?

Orthofix Medical issued an update on its FY 2021 earnings guidance on Friday, May, 7th. The company provided EPS guidance of 0.520-0.620 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.500. The company issued revenue guidance of $455 million-$465 million, compared to the consensus revenue estimate of $448.85 million.

What price target have analysts set for OFIX?

1 Wall Street analysts have issued 12 month target prices for Orthofix Medical's shares. Their forecasts range from $39.00 to $39.00. On average, they expect Orthofix Medical's share price to reach $39.00 in the next year. This suggests that the stock has a possible downside of 6.6%.
View analysts' price targets for Orthofix Medical
or view top-rated stocks among Wall Street analysts.

Who are Orthofix Medical's key executives?

Orthofix Medical's management team includes the following people:
  • Mr. Jon C. Serbousek, Pres, CEO & Director (Age 60, Pay $1.78M)
  • Mr. Douglas C. Rice, CFO & Chief Accounting Officer (Age 55, Pay $515.18k)
  • Ms. Kimberley A. Elting, Chief Legal & Devel. Officer (Age 56, Pay $508.05k)
  • Mr. Roberto Donadello, Sr. VP, Global Operations
  • Dr. James T. Ryaby B.A., Ph.D., Chemistry, Chief Scientific Officer (Age 62)
  • Mr. Tim McGuire, Chief Information Officer
  • Mr. Dan E. Yarbrough, VP of Investor Relations
  • Ms. Jill Mason, Chief Ethics & Compliance Officer
  • Ms. Suzanne Armstrong, VP of HR
  • Mr. Kevin J. Kenny, Pres of Global Spine Bus. (Age 56)

What is Brad Mason's approval rating as Orthofix Medical's CEO?

32 employees have rated Orthofix Medical CEO Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among Orthofix Medical's employees.

Who are some of Orthofix Medical's key competitors?

What other stocks do shareholders of Orthofix Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).

What is Orthofix Medical's stock symbol?

Orthofix Medical trades on the NASDAQ under the ticker symbol "OFIX."

Who are Orthofix Medical's major shareholders?

Orthofix Medical's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (16.71%), Paradice Investment Management LLC (4.99%), Factorial Partners LLC (4.45%), Dimensional Fund Advisors LP (3.36%), Renaissance Technologies LLC (3.28%) and Polar Asset Management Partners Inc. (3.28%). Company insiders that own Orthofix Medical stock include Brad Mason, James F Hinrichs, Jon Carl Serbousek and Ronald A Matricaria.
View institutional ownership trends for Orthofix Medical
.

Which major investors are selling Orthofix Medical stock?

OFIX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Northern Trust Corp, JPMorgan Chase & Co., Acadian Asset Management LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Gabelli Funds LLC, and Zebra Capital Management LLC.
View insider buying and selling activity for Orthofix Medical
or view top insider-selling stocks.

Which major investors are buying Orthofix Medical stock?

OFIX stock was bought by a variety of institutional investors in the last quarter, including Factorial Partners LLC, BlackRock Inc., Royce & Associates LP, Millennium Management LLC, Victory Capital Management Inc., Polar Asset Management Partners Inc., Lisanti Capital Growth LLC, and Ameriprise Financial Inc.. Company insiders that have bought Orthofix Medical stock in the last two years include James F Hinrichs, Jon Carl Serbousek, and Ronald A Matricaria.
View insider buying and selling activity for Orthofix Medical
or or view top insider-buying stocks.

How do I buy shares of Orthofix Medical?

Shares of OFIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orthofix Medical's stock price today?

One share of OFIX stock can currently be purchased for approximately $41.75.

How much money does Orthofix Medical make?

Orthofix Medical has a market capitalization of $816.59 million and generates $406.56 million in revenue each year. The medical device company earns $2.52 million in net income (profit) each year or $0.26 on an earnings per share basis.

How many employees does Orthofix Medical have?

Orthofix Medical employs 1,036 workers across the globe.

When was Orthofix Medical founded?

Orthofix Medical was founded in 1980.

What is Orthofix Medical's official website?

The official website for Orthofix Medical is www.orthofix.com.

Where are Orthofix Medical's headquarters?

Orthofix Medical is headquartered at 3451 Plano Parkway, Lewisville TX, 75056.

How can I contact Orthofix Medical?

Orthofix Medical's mailing address is 3451 Plano Parkway, Lewisville TX, 75056. The medical device company can be reached via phone at 214-937-2000 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.